Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAmortizatization of IntangiblesCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in CashChange in InventoryChange in InventoryChange in ReceivablesChange in ReceivablesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesGains from Sales and DivestituresGains from Sales and DivestituresLong-Term Debt IssuancesLong-Term Debt RepaymentsNet Cash FlowNet Cash FlowNet IncomeNon-cash ItemsNon-cash ItemsOther Working Capital ChangesOther Working Capital ChangesOther financing activitiesOther financing activitiesShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Cost of RevenueEBIATGross ProfitLeasesLong-Term Debt IssuancesLong-Term Debt RepaymentsMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsReceivables - NetShares IssuedShares OutstandingShares Outstanding
Ratios

Axsome Therapeutics (AXSM) Long-Term Debt Repayments (2018 - 2026)

Axsome Therapeutics recorded quarterly Long-Term Debt Repayments of $70.0 million in Q1 2026, little changed quarter-over-quarter from $70.0 million in Q4 2025.

Axsome Therapeutics' Long-Term Debt Repayments history runs 4 years deep, the most recent figure standing at $70.0 million for Q1 2026.

  • In Q1 2026, Long-Term Debt Repayments changed N/A year-over-year to $70.0 million; the TTM figure through Mar 2026 stood at $210.0 million (changed N/A YoY), while the FY2025 annual figure was $332.0 million, changed N/A from the prior year.
  • Long-Term Debt Repayments came in at $70.0 million for Q1 2026 at Axsome Therapeutics, roughly flat from $70.0 million in the prior quarter.
  • In the past five years, Long-Term Debt Repayments ranged from a high of $70.0 million in Q3 2025 to a low of $70.0 million in Q3 2025.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Long-Term Debt Repayments (Qtr)
1 Quantum Biopharma 961,148.99 Bn 961,148.98 Bn - -
2 Alterity Therapeutics 744,933.29 Bn 744,933.26 Bn - -
3 Legend Biotech 2,540.00 Bn 2,539.71 Bn 242.10 Mn -
4 Nanobiotix 2,199.85 Bn 2,199.78 Bn - -
5 Akari Therapeutics 1,635.88 Bn 1,635.88 Bn - -
6 Vertex Pharmaceuticals 111.32 Bn 104.07 Bn 2.59 Bn -
7 Evaxion A 62.56 Bn 62.54 Bn - -
8 Regeneron Pharmaceuticals 62.55 Bn 53.79 Bn 3.31 Bn -
9 Alnylam Pharmaceuticals 39.57 Bn 36.56 Bn 959.66 Mn -
10 Axsome Therapeutics 11.82 Bn 11.51 Bn 176.48 Mn 70.00 Mn

Historic Data

Download Data 🔒
DateValue
Mar 31, 2026 70.00 Mn
Mar 31, 2026 70.00 Mn
Dec 31, 2025 70.00 Mn
Dec 31, 2025 70.00 Mn
Sep 30, 2025 70.00 Mn
Sep 30, 2025 70.00 Mn
Jun 30, 2019 1.64 Mn
Jun 30, 2019 1.64 Mn
Mar 31, 2019 5.60 Mn
Mar 31, 2019 5.60 Mn
Dec 31, 2018 833,333.00
Dec 31, 2018 833,333.00
Sep 30, 2018 833,333.00
Sep 30, 2018 833,333.00
Jun 30, 2018 833,334.00
Jun 30, 2018 833,334.00
Mar 31, 2018 833,333.00
Mar 31, 2018 833,333.00